Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$737.1 million.

  • Ocular Therapeutix's Enterprise Value fell 8797.66% to -$737.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$737.1 million, marking a year-over-year decrease of 8797.66%. This contributed to the annual value of -$737.1 million for FY2025, which is 8797.66% down from last year.
  • As of Q4 2025, Ocular Therapeutix's Enterprise Value stood at -$737.1 million, which was down 8797.66% from -$344.8 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Enterprise Value registered a high of -$66.6 million during Q2 2023, and its lowest value of -$737.1 million during Q4 2025.
  • Over the past 5 years, Ocular Therapeutix's median Enterprise Value value was -$193.9 million (recorded in 2021), while the average stood at -$264.2 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 5049.32% in 2023, then tumbled by 59016.3% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Enterprise Value stood at -$164.2 million in 2021, then skyrocketed by 37.68% to -$102.3 million in 2022, then crashed by 91.55% to -$196.0 million in 2023, then crashed by 100.1% to -$392.1 million in 2024, then plummeted by 87.98% to -$737.1 million in 2025.
  • Its Enterprise Value stands at -$737.1 million for Q4 2025, versus -$344.8 million for Q3 2025 and -$391.1 million for Q2 2025.